There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility.
Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/
Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime.
It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent.
Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.
It’s inevitable that we’re all going to age, but Dr. Ronald Kaiser has discovered a way to make it enjoyable. In his new book Rejuvenaging: The Art and Science of Growing Older with Enthusiasm, Dr. Kaiser lays out the path to not only embracing our later years but making them the best half of our lives. Drawing on more than a half-century of clinical experience, and 80 years of living, Kaiser shares his simple plan to success. Find out more at http://www.thementalhealthgym.com/ Non-Fiction/Self Help
Continuing a legacy of artistic collaboration that spans centuries, Hennessy welcomes multi-disciplinary artist Ryan McGinness as the designer of the new Hennessy V.S Limited Edition bottle. McGinness’ take on the iconic Hennessy V.S label features a distinctive radiant pattern in fluorescent colors that glow under black light, and is now available for purchase online and at select wine & spirits retailers nationwide.
Known for using the visual language of contemporary symbology, the New York-based McGinness is credited with elevating the status of the icon to fine art. His works have been exhibited in museums around the world.
The new Hennessy V.S Limited Edition is the fifth in a series that has included critically acclaimed artists, KAWS, Futura, Os Gemêos and Shepard Fairey, the collaboration with McGinness is a perfect embodiment of Hennessy’s 250 years of dedication to the art of blending. McGinness acknowledges the strong similarities between his artistic approach and the creation of Hennessy Cognac: “My process of combining elements and compounds to form mixtures parallels Hennessy’s artful blending of eaux-de-vie to create Cognac. The shared approach to our crafts is part science and part art.”
To view the multimedia release please visit:
http://www.multivu.com/players/English/7582851-hennessy-ryan-mcginness-limited-edition/
Corporates today are on the lookout of new and novel ways to use their CSR funds effectively. A genuine step towards improving the quality of education in urban and especially rural areas would definitely interest them. And to make this possible, STEM Learning Pvt Ltd has launched Mini Science Centres (MSC) to promote experiential learning. STEM Learning is a pioneer in installing Mini Science Centres at schools in India. So far, they have installed over 40 Mega Science Centres and 250+ Mini Science Centres in Maharashtra, Gujarat, Chhattisgarh, Goa, Karnataka and Rajasthan. Their aim is to reach one million students from rural as well as urban areas of the country.
The Mini Science Project is an innovative concept developed by STEM Learning and consists of 60+ table-top models that are designed as per the syllabus of SSC, CBSC and ICSE Boards. These models come with a two-year warranty and maintenance. STEM learning also provides training to teachers to improve the effectiveness of these models in English and other vernacular languages.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7561751-stem-learning-mini-science-centre/
www.LegendsofAmunRa.com
One of the best science fiction books of the year is here, The Soul of the World, book 2 in the series Legends of Amun Ra
The ancient powers lost to Potara have returned. The Brotherhood of the Black Rose rises to bring Thoth into disorder. And, while the Brotherhood reclaims their power, chaos reigns among the survivors. Six individuals have emerged from the aftermath struggling for control over their lives and a divided land. Kem and Shirin, who abolished the five thousand year reign of the Amun Priests, rule from the golden throne of the Oracle’s Chair in the Hall of the Nine. Dio and Axios struggle to piece together a resistance worthy to challenge the ancient magic which resides in the Great Temple of Amun, and Leoros and Atlantia try to remain true to their hearts and their cause despite tragedy.
But when the Book of Breathings is discovered, the path to immortality is revealed. Leoros and Kem race to capture the Soul of the World unaware of the challenges awaiting them. This time, the gods themselves will intervene. A must read, best science fiction books of the year
In a tale where boys become men and girls become women, where treachery and deception are around every corner, and where primeval mysticism finds its way back from the grave, victory is reserved for neither the good nor the evil, but the powerful.
Join the journey to one of the best science fiction books in 2013.
www.LegendsofAmunRa.com
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
SAIC, Inc. (NYSE: SAI) today held an Investor Day event in New York City in which the senior leadership team of the planned spin-off company, Science Applications International Corp. (SAIC), presented its business plans and financial objectives.
SAIC, Inc. previously announced plans to create two independent, publicly traded companies. Upon completion of the planned spin-off transaction, the technical, engineering and enterprise IT services business will retain the name SAIC and trade under (NYSE: SAIC), while the government and commercial solutions company will be named Leidos and trade under (NYSE: LDOS).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63326-saic-presents-planned-company-s-business-financial-objectives-investor-day
Carlsberg is celebrating its unique history with the re-launch of six of their its vintage labels, each telling a story of how the Danish beer company has been a first-mover in everything from long beards to international shipping.
From the creators of the pH scale and the first pure brewer’s yeast, the company that donates significant proportions of its earnings to support science, art and culture through the Carlsberg Foundation, and the company for whom phrases like “Open-Source” and “Corporate Social Responsibility” were part of the vocabulary centuries ago…
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7526351-carlsberg-worlds-best-labels/
Carlsberg is celebrating its unique history with the re-launch of six of their its vintage labels, each telling a story of how the Danish beer company has been a first-mover in everything from long beards to international shipping.
From the creators of the pH scale and the first pure brewer’s yeast, the company that donates significant proportions of its earnings to support science, art and culture through the Carlsberg Foundation, and the company for whom phrases like “Open-Source” and “Corporate Social Responsibility” were part of the vocabulary centuries ago…
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7526351-carlsberg-worlds-best-labels/
In Carbide Tipped Pens, over a dozen of today’s most creative imaginations explore these frontiers, carrying on the grand tradition of such legendary masters as Isaac Asimov, Robert Heinlein, and John W. Campbell, while bringing hard science fiction into the 21st century by extrapolating from the latest scientific developments and discoveries. Find out more at http://us.macmillan.com/books/9780765334305. Science fiction
